Clinical Trials
14 trialsNCT04164199 2026-06-03
Study of Tislelizumab, Pamiparib, and Other Investigational Agents in Participants With Advanced Malignancies
BeOne Medicines
Phase 3 Completed
NCT06324357 2026-05-26
Beamion BCGC-1: A Study to Find a Suitable Dose of Zongertinib Used Alone and in Combination With Other Treatments to Test Whether it Helps People With Different Types of HER2+ Cancer That Has Spread
Boehringer Ingelheim
Phase 1/2 Recruiting
NCT05152147 2026-05-19
HERIZON-GEA-01
Jazz Pharmaceuticals
Phase 3 Active not recruiting
NCT06282575 2026-05-11
Efficacy and Safety of Zanidatamab With Standard-of-care Therapy Against Standard-of-care Therapy for Advanced HER2-positive Biliary Tract Cancer
Jazz Pharmaceuticals
Phase 3 Recruiting
NCT07102381 2026-04-29
EmpowHER 208
Jazz Pharmaceuticals
Phase 2 Recruiting
NCT06695845 2026-04-09
A Phase 2 Study of Zanidatamab in Patients With HER2-expressing Tumors
Jazz Pharmaceuticals
Phase 2 Recruiting
NCT06435429 2026-02-10
A Study Comparing the Efficacy and Safety of Zanidatamab to Trastuzumab, Each in Combination With Physician's Choice Chemotherapy, for the Treatment of Participants With Metastatic HER2-positive Breast Cancer
Jazz Pharmaceuticals
Phase 3 Recruiting
NCT05027139 2025-10-16
A Study of Zanidatamab (ZW25) With Evorpacept (ALX148) in Patients With Advanced HER2-expressing Cancer
Jazz Pharmaceuticals
Phase 1/2 Completed
NCT04466891 2025-09-15
HERIZON-BTC-01
Jazz Pharmaceuticals
Phase 2 Completed
NCT03929666 2025-09-12
A Safety and Efficacy Study of ZW25 (Zanidatamab) Plus Combination Chemotherapy in HER2-expressing Gastrointestinal Cancers, Including Gastroesophageal Adenocarcinoma, Biliary Tract Cancer, and Colorectal Cancer
Jazz Pharmaceuticals
Phase 2 Completed
NCT04224272 2025-08-01
A Study of ZW25 (Zanidatamab) With Palbociclib Plus Fulvestrant in Patients With HER2+/HR+ Advanced Breast Cancer
Jazz Pharmaceuticals
Phase 2 Completed
NCT04578444 2025-05-25
An Expanded Access Treatment Protocol of Zanidatamab (ZW25) in Patients With HER2-Positive Advanced Biliary Tract Cancer
Jazz Pharmaceuticals
No longer available
NCT04276493 2024-12-06
Anti-HER2 Bispecific Antibody Zanidatamab (ZW25) Activity in Combination With Chemotherapy With/Without Tislelizumab
BeiGene
Phase 1/2 Completed
NCT02892123 2024-11-27
Trial of ZW25 (Zanidatamab) in Patients With Advanced HER2-expressing Cancers
Jazz Pharmaceuticals
Phase 1 Completed